Molecular BiologybioRxivPreprint
Low dose AKT inhibitor miransertib cures PI3K-related vascular malformations in preclinical models of human disease
Piotr Kobialka, Helena Sabata, Odena Vilalta…·Mariona Graupera
The paper develops a preclinical model of PI3K-driven vascular malformations and shows that low-dose AKT inhibitor miransertib prevents and regresses these malformations in mice and human endothelial cells.
5 citations